Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

被引:11
作者
Jaradat, Sara K. [1 ]
Ayoub, Nehad M. [1 ]
Al Sharie, Ahmed H. [2 ]
Aldaod, Julia M. [1 ]
机构
[1] Jordan Univ Sci & Technol JUST, Fac Pharm, Dept Clin Pharm, POB 3030, Irbid 22110, Jordan
[2] Jordan Univ Sci & Technol JUST, Fac Med, Dept Pathol & Microbiol, Irbid, Jordan
关键词
triple-negative breast cancer; receptor tyrosine kinases; small-molecule inhibitors; EGFR; MET; AXL; GROWTH-FACTOR RECEPTOR; POTENTIAL THERAPEUTIC TARGET; FACTOR-I RECEPTOR; GENE COPY NUMBER; CELL LUNG-CANCER; C-KIT; BIOLOGICAL SUBTYPES; CABOZANTINIB XL184; INHIBITS GROWTH; DOWN-REGULATION;
D O I
10.1177/15330338241234780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors. Nevertheless, the success of chemotherapeutic treatments is limited by their toxicity and development of acquired resistance leading to therapeutic failure and tumor relapse. Hence, there is an urgent need to explore novel targeted therapies for TNBC. Receptor tyrosine kinases (RTKs) are a family of transmembrane receptors that are key regulators of intracellular signaling pathways controlling cell proliferation, differentiation, survival, and motility. Aberrant activity and/or expression of several types of RTKs have been strongly connected to tumorigenesis. RTKs are frequently overexpressed and/or deregulated in triple-negative breast tumors and are further associated with tumor progression and reduced survival in patients. Therefore, targeting RTKs could be an appealing therapeutic strategy for the treatment of TNBC. This review summarizes the current evidence regarding the antitumor activity of RTK inhibitors in preclinical models of TNBC. The review also provides insights into the clinical trials evaluating the use of RTK inhibitors for the treatment of patients with TNBC.
引用
收藏
页数:20
相关论文
共 183 条
[131]   Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines [J].
Simiczyjew, Aleksandra ;
Dratkiewicz, Ewelina ;
Van Troys, Marleen ;
Ampe, Christophe ;
Styczen, Ilona ;
Nowak, Dorota .
CANCERS, 2018, 10 (09)
[132]   Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers [J].
Song, W. ;
Hwang, Y. ;
Youngblood, V. M. ;
Cook, R. S. ;
Balko, J. M. ;
Chen, J. ;
Brantley-Sieders, D. M. .
ONCOGENE, 2017, 36 (40) :5620-5630
[133]   Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].
Sorlie, T ;
Perou, CM ;
Tibshirani, R ;
Aas, T ;
Geisler, S ;
Johnsen, H ;
Hastie, T ;
Eisen, MB ;
van de Rijn, M ;
Jeffrey, SS ;
Thorsen, T ;
Quist, H ;
Matese, JC ;
Brown, PO ;
Botstein, D ;
Lonning, PE ;
Borresen-Dale, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874
[134]  
Steelman Linda S., 2020, Advances in Biological Regulation, V78, P100758, DOI 10.1016/j.jbior.2020.100758
[135]  
Sulai NH, 2018, CLIN ADV HEMATOL ONC, V16, P491
[136]   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249
[137]   RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells [J].
Suthe, Sreedhar Reddy ;
Yao, Hang-Ping ;
Weng, Tian-Hao ;
Wang, Ming-Hai .
CURRENT CANCER DRUG TARGETS, 2023, 23 (02) :103-117
[138]   RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE [J].
Suthe, Sreedhar Reddy ;
Yao, Hang-Ping ;
Weng, Tian-Hao ;
Hu, Chen-Yu ;
Feng, Liang ;
Wu, Zhi-Gang ;
Wang, Ming-Hai .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) :2654-2664
[139]   FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells [J].
Taliaferro-Smith, LaTonia ;
Oberlick, Elaine ;
Liu, Tongrui ;
McGlothen, Tanisha ;
Alcaide, Tiffanie ;
Tobin, Rachel ;
Donnelly, Siobhan ;
Commander, Rachel ;
Kline, Erik ;
Nagaraju, Ganji Purnachandra ;
Havel, Lauren ;
Marcus, Adam ;
Nahta, Rita ;
O'Regan, Ruth .
ONCOTARGET, 2015, 6 (07) :4757-4772
[140]   Impact of Expression of Vimentin and Axl in Breast Cancer [J].
Tanaka, Kimihiro ;
Tokunaga, Eriko ;
Inoue, Yuka ;
Yamashita, Nami ;
Saeki, Hiroshi ;
Okano, Shinji ;
Kitao, Hiroyuki ;
Oki, Eiji ;
Oda, Yoshinao ;
Maehara, Yoshihiko .
CLINICAL BREAST CANCER, 2016, 16 (06) :520-526